Product
Liposomal Amphotericin B
3 clinical trials
8 indications
Indication
Leishmaniasis; BrazilianIndication
LeishmaniasisIndication
MucocutaneousIndication
MucormycosisIndication
HistoplasmosisIndication
HIV/AIDSIndication
Immune suppressionIndication
Fungal InfectionClinical trial
Pilot Study: Oral Treatment of American Tegumentary Leishmaniasis (Cutaneous and Mucosal Forms) in the ElderlyStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Randomized Controlled Trial of Amphotericin B Versus Posaconazole for Treating Pulmonary MucormycosisStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
Efficacy and Safety of High-dose Liposomal Amphotericin B (10 mg/kg) for Disseminated Histoplasmosis in AIDS: a Randomized Phase III Trial (INDUCTION Trial)Status: Not yet recruiting, Estimated PCD: 2025-05-28